We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Prothena (PRTA) to Sell ATTR Amyloidosis Program to Novo Nordisk
Read MoreHide Full Article
Prothena Corporation (PRTA - Free Report) announced a collaboration with Denmark-based Novo Nordisk (NVO - Free Report) , whereby the latter will acquire Prothena’s clinical-stage antibody, PRX004, and broader ATTR amyloidosis program.
In exchange, Prothena is eligible to receive development and sales milestone payments of approximately $1.2 billion, including $100 million in upfront and near-term clinical milestone payments.
The candidate is a phase II-ready, anti-amyloid immunotherapy designed to deplete the amyloid deposits that are associated with the disease pathology of ATTR amyloidosis. Prothena has completed a phase I open-label, multicenter dose-escalation study of PRX004 in patients with hereditary forms of ATTR. In the study, 21 patients with hereditary ATTR Amyloidosis (hATTR) were enrolled to receive PRX004 intravenously once every 28 days for up to 3 infusions in the dose-escalation phase of the study. The eligible patients who completed dose-escalation were provided the opportunity to enroll in the long-term extension (LTE) portion of the study.
Novo Nordisk will develop the phase II antibody, PRX004, for the rare heart disease, ATTR cardiomyopathy, which is an underdiagnosed and potentially fatal form of ATTR amyloidosis, characterized by the build-up of amyloid deposits in cardiac tissue.
The decision to sell its ATTR amyloidosis program comes at a strategic point for the company. The company’s pipeline includes programs for the potential treatment of Alzheimer’s disease (AD), including PRX012 that targets Aβ (Amyloid beta). The partnered programs include prasinezumab, in collaboration with Roche (RHHBY - Free Report) , for the potential treatment of Parkinson’s disease and other related synucleinopathies, and programs that target tau (PRX005), TDP-43, and an undisclosed target in collaboration with Bristol Myers Squibb for the potential treatment of AD, amyotrophic lateral sclerosis (ALS), or other neurodegenerative diseases.
Shares of the company have surged 352.9% in the year so far against the industry's decline of 2%.
Image Source: Zacks Investment Research
Most of the upside came after the FDA approval of Biogen’s (BIIB - Free Report) Alzheimer's disease (AD) drug, Aduhelm. On Jun 7, 2021, Biogen and partner Eisai won the FDA approval for Aduhelm (aducanumab-avwa) as the first and only AD treatment.
The approval has brought the spotlight on other companies as well who are developing drugs for AD and investors are optimistic about the prospects of these pipeline candidates. Prothena’s PRX005 is being evaluated for the treatment of AD. The company has another candidate, PRX012, which is a potential treatment for AD.
The divestment of its ATTR amyloidosis program will enable Prothena to focus on its neurodegenerative drugs.
Meanwhile, the abovementioned acquisition will diversify Novo Nordisk’s diabetes and obesity portfolio.
Image: Bigstock
Prothena (PRTA) to Sell ATTR Amyloidosis Program to Novo Nordisk
Prothena Corporation (PRTA - Free Report) announced a collaboration with Denmark-based Novo Nordisk (NVO - Free Report) , whereby the latter will acquire Prothena’s clinical-stage antibody, PRX004, and broader ATTR amyloidosis program.
In exchange, Prothena is eligible to receive development and sales milestone payments of approximately $1.2 billion, including $100 million in upfront and near-term clinical milestone payments.
The candidate is a phase II-ready, anti-amyloid immunotherapy designed to deplete the amyloid deposits that are associated with the disease pathology of ATTR amyloidosis. Prothena has completed a phase I open-label, multicenter dose-escalation study of PRX004 in patients with hereditary forms of ATTR. In the study, 21 patients with hereditary ATTR Amyloidosis (hATTR) were enrolled to receive PRX004 intravenously once every 28 days for up to 3 infusions in the dose-escalation phase of the study. The eligible patients who completed dose-escalation were provided the opportunity to enroll in the long-term extension (LTE) portion of the study.
Novo Nordisk will develop the phase II antibody, PRX004, for the rare heart disease, ATTR cardiomyopathy, which is an underdiagnosed and potentially fatal form of ATTR amyloidosis, characterized by the build-up of amyloid deposits in cardiac tissue.
The decision to sell its ATTR amyloidosis program comes at a strategic point for the company. The company’s pipeline includes programs for the potential treatment of Alzheimer’s disease (AD), including PRX012 that targets Aβ (Amyloid beta). The partnered programs include prasinezumab, in collaboration with Roche (RHHBY - Free Report) , for the potential treatment of Parkinson’s disease and other related synucleinopathies, and programs that target tau (PRX005), TDP-43, and an undisclosed target in collaboration with Bristol Myers Squibb for the potential treatment of AD, amyotrophic lateral sclerosis (ALS), or other neurodegenerative diseases.
Shares of the company have surged 352.9% in the year so far against the industry's decline of 2%.
Image Source: Zacks Investment Research
Most of the upside came after the FDA approval of Biogen’s (BIIB - Free Report) Alzheimer's disease (AD) drug, Aduhelm. On Jun 7, 2021, Biogen and partner Eisai won the FDA approval for Aduhelm (aducanumab-avwa) as the first and only AD treatment.
The approval has brought the spotlight on other companies as well who are developing drugs for AD and investors are optimistic about the prospects of these pipeline candidates. Prothena’s PRX005 is being evaluated for the treatment of AD. The company has another candidate, PRX012, which is a potential treatment for AD.
The divestment of its ATTR amyloidosis program will enable Prothena to focus on its neurodegenerative drugs.
Meanwhile, the abovementioned acquisition will diversify Novo Nordisk’s diabetes and obesity portfolio.
Prothena currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.